Allakos sustains its gains on strength of GI readout

Not even the dilution of an upsized follow-on offering could slow Allakos' momentum as its share price marched north steadily through midweek on the strength of Phase II data in eosinophilic gastrointestinal disorders, suggesting investors are betting the company is ripe for a takeout.